Cargando…
Increased epithelial membrane protein 2 expression in glioblastoma after treatment with bevacizumab
BACKGROUND: Antiangiogenic therapy with bevacizumab has failed to provide substantial gains in overall survival. Epithelial membrane protein 2 (EMP2) is a cell surface protein that has been previously shown to be expressed in glioblastoma, correlate with poor survival, and regulate neoangiogenesis i...
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7542982/ https://www.ncbi.nlm.nih.gov/pubmed/33063013 http://dx.doi.org/10.1093/noajnl/vdaa112 |